“Was Sexism Really Responsible for the FDA’s Hesitancy to Sign Off on Flibanserin?”

0
154

“The Food and Drug Administration’s approval of pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex,” Maya Dusenbery writes in the Pacific Standard. Is “female Viagra” a feminist victory or a product of clever faux-feminist marketing by Big Pharma?

Article →

LEAVE A REPLY